SELL and COVID-19: However, severe COVID-19 patients had more CTLA-4+ CD62L+ cells (Figure 1C, p=0.01) and PD-1+ CD62L+ cells (Figure 1D, p=0.049) in the total CD4+ population compared to non-severe patients.